HSPD1 and non-small cell lung carcinoma: This is a very important observation in line with the observed inability of death pathways inhibitors to protect in vitro from KHS101, and in line with the data from the two independent fitness analyses on HSPD1 gene and with the drug screening from large collections of NSCLC cell lines of various genetic backgrounds, which confirmed that no single genetic alteration can guarantee a complete protection from the treatment with KHS101.